Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin D analogs in the prevention of cardiovascular diseases by Pacini, Stefania et al.
Nutrients 2013, 5, 2076-2092; doi:10.3390/nu5062076 
 
nutrients 
ISSN 2072-6643 
www.mdpi.com/journal/nutrients 
Article 
Effects of Vitamin D3 and Paricalcitol on Immature 
Cardiomyocytes: A Novel Role for Vitamin D Analogs in the 
Prevention of Cardiovascular Diseases 
Stefania Pacini 
1
, Gabriele Morucci 
1
, Jacopo J. V. Branca 
1
, Stefano Aterini 
2
, Marcello Amato 
2
, 
Massimo Gulisano 
1
 and Marco Ruggiero 
3,
* 
1
 Department of Experimental and Clinical Medicine, University of Firenze, 50134 Firenze, Italy;  
E-Mails: stefania.pacini@unifi.it (S.P.); gabriele.morucci@unifi.it (G.M.);  
jacopo.branca@libero.it (J.J.V.B.); massimo.gulisano@unifi.it (M.G.) 
2 
Division of Nephrology and Hemodialysis, Prato Hospital, 59100 Prato, Italy;  
E-Mails: saterini@usl4.toscana.it (S.A.); mamato@usl4.toscana.it (M.A.) 
3 
Department of Biomedical, Experimental and Clinical Sciences, University of Firenze,  
50134 Firenze, Italy 
* Author to whom correspondence should be addressed; E-Mail: marco.ruggiero@unifi.it;  
Tel.: +39-055-4598213; Fax: +39-055-4379500. 
Received: 15 April 2013; in revised form: 23 May 2013 / Accepted: 24 May 2013 /  
Published: 7 June 2013 
 
Abstract: Cardiovascular diseases are more prevalent in patients with chronic kidney 
disease than in the general population and they are considered the leading cause of  
death in patients with end-stage renal disease. The discovery that vitamin D3 plays a 
considerable role in cardiovascular protection has led, in recent years, to an increase in the 
administration of therapies based on the use of this molecule; nevertheless, several studies 
warned that an excess of vitamin D3 may increase the risk of hypercalcemia and vascular 
calcifications. In this study we evaluated the effects of vitamin D3, and of its selective 
analog paricalcitol, on immature cardiomyocytes. Results show that vitamin D3 induces 
cAMP-mediated cell proliferation and significant intracellular calcification. Paricalcitol, 
however, induces cell differentiation, morphological modifications in cell shape and size, 
and no intracellular calcification. Furthermore, vitamin D3 and paricalcitol differently 
affect cardiomyoblasts responses to acetylcholine treatment. In conclusion, our results 
demonstrate that the effects of vitamin D3 and paricalcitol on cardiomyoblasts are different 
and, if these in vitro observations could be extrapolated in vivo, they suggest that 
OPEN ACCESS 
Nutrients 2013, 5 2077 
 
 
paricalcitol has the potential for cardiovascular protection without the risk of inducing 
intracellular calcification. 
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1. Introduction 
The National Kidney Foundation Task Force on Cardiovascular Disease recommends that chronic 
kidney disease (CKD) patients be considered among the highest risk group for developing 
cardiovascular (CV) disease [1]. In fact, CV disease is more prevalent in patients with CKD than in the 
general population [2] and it is the leading cause of death in patients with end-stage renal disease [1]. It 
has been reported that nearly 30% of deaths among patients with CKD are to be attributed to 
cardiovascular causes [3]. 
CKD associated hyperparathyroidism and mineral metabolism disorders, such as hyperphosphatemia, 
have been significantly correlated with vascular and visceral calcifications, and consequently with 
increased risk of CV disease [4].  
In addition to vascular problems, left ventricular hypertrophy, subclinical systolic dysfunction, and 
diastolic dysfunction have been consistently observed in subjects with CKD [5]. It is conjectured that 
abnormal diastolic function is an independent predictor of decreased aerobic capacity during the early 
stages of CKD [6].  
Nevertheless, even though numerous factors have been implicated in the aetiology of the cardiac 
abnormalities observed in patients with CKD, the exact aetiology of the observed cardiac changes still 
remains unclear. A number of cardiac pathologies, including heart failure, are associated with 
alterations in myocardial energy metabolism [7] as well as with the activation of different intracellular 
signal transduction pathways.  
Vitamin D3 (in its active form, i.e., calcitriol or 1,25-dihydroxyvitamin D3), as many other  
direct-acting positive inotropic agents, stimulates cyclic AMP (cAMP) formation [8], a major mediator 
of the amplitude and time course of cardiac contraction [8]. This cAMP-mediated inotropic effect 
occurs through activation of a variety of cAMP-dependent protein kinases that are capable of 
phosphorylating a series of proteins that affect the energetic status of the cells and alter the flux of 
calcium in the sarcoplasm [8]. 
In fact, calcium release and energetic systems are strictly and subtly modulated by different 
molecules, and an imbalance of sympathetic and parasympathetic drive to the heart represents an 
important risk factor for cardiac death in patients with renal insufficiency [9].  
Since vitamin D3, together with dietary restrictions and phosphate binders, represents the primary 
medication to treat secondary hyperparathyroidism and the associated calcium and phosphate 
metabolic alterations in CKD, interest in the role of vitamin D3 axis in the cardiovascular system 
recently increased. Thus, the vitamin D axis, which plays a critical role in the development of CKD, 
includes vitamin D, the polymorphic vitamin D receptor (VDR), and the vitamin D-binding protein 
(Gc-globulin) [10]. That is the precursor of a potent macrophage activating factor (GcMAF), which 
has potent effects on the immune system and angiogenesis [11].  
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In parallel, with this interest for beneficial effects [12], however, other studies warned that  
an excess of vitamin D3 increases the risk of hypercalcemia and vascular calcifications thus increasing 
the risk for CV and reducing survival in patients with CKD [13,14]. 
In this study we investigated the effect of vitamin D3 as well as of one of its non-hypercalcemic 
analogs, paricalcitol, on cultured cardiomyocytes. Paricalcitol (19-nor-1,25-dihydroxyvitamin D2) is  
a vitamin D3 analog, acting as a selective VDR activator; for this reason it might provide  
a vitamin D3-like protective efficacy without the hypercalcemic and hypophosphatemic side effects of 
vitamin D3, thus representing a potentially useful tool against the cardio-renal syndrome [12,15].  
In particular, to better evaluate the modifications of the intracellular energy status as well as the 
modifications in signal transduction, in this study we compared the effects of vitamin D3, to those of 
paricalcitol in a myoblastic cell line H9c2, not completely differentiated showing electrophysiological 
and biochemical properties of cardiac muscle tissue [16]. Proliferation, mitochondrial activity, 
morphological alterations, calcification, cAMP pathway activation, and response to acetylcholine were 
thus investigated. 
2. Experimental Section 
2.1. Pharmacological Agents 
Vitamin D3 and Paricalcitol were respectively obtained from Sigma Aldrich, Milano, Italy and from 
Abbott, Roma, Italy. Due to differences in test compounds, two different treatment vehicles were used 
during the study: 100% ethanol (for vitamin D3) and 30% polyethylene glycol/20% ethanol in water 
(for paricalcitol). Preliminary experiments did not show significant differences among different 
concentrations of vehicles in cell responses (not shown). Therefore, the different vehicle 
concentrations data were pooled for the analysis in this report. Vitamin D binding protein-derived 
macrophage activating factor (GcMAF) was obtained from Immuno Biotech Ltd. (Guernsey, Channel 
Islands). β-Glycerol-phosphate (β-GP), ethanol, polyethylene glycol, and acetylcholine were obtained 
from Sigma Aldrich, Milano, Italy.  
2.2. Cell Cultures 
H9c2 cells, immortalized ventricular myocytes derived from rat (Rattus norvegicus) embryos, were 
obtained from the “Istituto Zooprofilattico della Lombardia e dell’Emilia Romagna”, Brescia, Italy. 
H9c2 is a myoblast cell line not yet completely differentiated into non-proliferating myocytes/myotubes 
and with electrophysiological and biochemical properties of both skeletal and cardiac muscle tissue. 
Cell were grown in a monolayer culture at 37 °C in a 5% CO2 humidified atmosphere in Dulbecco’s 
modified eagle’s medium (DMEM) supplemented with 10% foetal bovine serum (FBS). The medium 
was renewed every two to three days, when the cells reached sub-confluence (70%–80%). Vitamin D3 
and paricalcitol were added to the cells at the following concentrations: [1 nM], [10 nM], [100 nM], 
and [300 nM]. Treatment with acetylcholine was performed with and without vitamin D3 and 
paricalcitol [300 nM] at the concentration of [10 μM] for 1 h.  
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2.3. Cell Viability and Proliferation  
The effects of vitamin D3 and paricalcitol on H9c2 cell lines, were evaluated by the cell viability 
assay using the 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulf-ophenyl)-2H tetrazolium 
monosodium salt (WST-8) reagent (Sigma Aldrich, Milano, Italy), according to the manufacturer’s 
protocol. This test is based on a colorimetric conversion of a tetrazolium salt (WST-8) to water-soluble 
formazan products as previously described [17]. H9c2 cells were plated at density of 2 × 10
4
 per well 
in a 96-well plate with fresh growth medium for one day. Then, vitamin D3 and paricalcitol were 
diluted to appropriate concentration and added to the culture medium for 48 h. After the  
exposure-time, WST-8 solution was added to each well and the micro-plate incubated for 4 h at 37 °C. 
Cell viability was measured by a micro-plate reader (Multiscan FC/FL6111900 model, Thermo Fisher 
Scientific, M-Medical, Milano, Italy) at 450 nm after incubation-time. To directly evaluate cell 
proliferation, a cell count by a haemocytometer (Housser Scientific, Horsham, PA, USA) was also 
performed. Also the evaluation of cardiomyocytes response to acetylcholine in the presence of  
vitamin D3 and paricalcitol was evaluated by cell viability assay. In each experiment, at least seven 
wells were used for each experimental point. 
2.4. Cell Morphology  
To evaluate changes in H9c2 cell morphology before and after vitamin D3 and paricalcitol 
exposure, contrast phase microscopy and Haematoxylin-Eosin staining were performed. 
Briefly, H9c2 cells were seeded on a cover slip at the density of 10 × 10
4
 cells/cover slip. 
Cells were grown in culture medium with different concentrations of vitamin D3 and paricalcitol for 
48 h. For the Haematoxylin-Eosin staining, H9c2 cells were fixed with paraformaldehyde 0.5% in [0.1 M] 
PBS (phosphate buffer saline) and dried for 2 h. Then, cells were stained with Haematoxylin-Eosin dye 
following a standard protocol. 
Cell morphology was evaluated by optical microscope (XDS-2 + M-795 model, Optika Microscope, 
Milano, Italy) and digital images were captured. 
After the treatment at different concentration of vitamin D3 and paricalcitol for 48 h, cell size of 
H9c2 was measured by Adobe Pohotoshop CS2 software (9.0 version, Adobe System Incorporated 
1990–2005; Adobe Systems Inc., San Jose, CA, USA) and Scion Image software (Beta 3b freeware 
version; based on NIH Image for Macintosh by Wayne Rasband, National Institute of Health, USA and 
modified for Windows by Scion Corporation; July, the 23rd 1998; Scion Co., Frederick, MD, USA). 
Images of H9c2 in Haematoxylin-Eosin staining were captured using a digital camera  
(DIGI-full HD video/photo camera, Optika Microscopes, Milano, Italy). Digital images were adjusted 
by Adobe Photoshop CS2 to remove from the picture everything (background) except the cells and 
then H9c2 cells size was measured by Scion Image. 
2.5. cAMP Assay 
H9c2 cells were cultured at density of 1 × 10
4
 cells per well in a 6-well plate with DMEM 
supplemented with 10% FBS and exposed at [1 nM], [10 nM], [100 nM], and [300 nM] vitamin D3 
and paricalcitol for 48 h. The cAMP intracellular level was evaluated by a direct competitive 
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immunoassay for sensitive and quantitative determination using a cAMP assay kit (Abnova, Heidelberg, 
Germany) according to the Manufacturer’s instructions. After the treatments, the experiment was 
blocked adding [0.1 M] HCl. Then, after scraping cells from the substrate, the suspension was 
centrifuged for 10 min at 2340 rpm. The supernatant was assayed for cAMP concentration by a  
micro-plate reader (Multiscan FC/FL6111900 model, Thermo Fisher Scientific, M-Medical, Milano, 
Italy) at 450 nm after incubation-time. cAMP values were normalized to the assayed proteins. 
2.6. Analysis of H9c2 Calcification 
To evaluate the deposits of calcium in H9c2 after vitamin D3 and Paricalcitol exposure, cells were 
seeded on cover slip at density 10 × 10
4
 per cover slip and cultured in their culture medium (DMEM + 
10% FBS). The medium was substituted with fresh culture medium every two days. After five days 
from confluence, fresh medium containing different concentration of vitamin D3 and paricalcitol was 
used for a further seven days. To amplify the calcification effects of vitamin D3 and paricalcitol,  
the medium was enriched with [4 mM] β-GP (calcification media). Quantification of calcium deposits 
was performed by von Kossa staining (von Kossa Kit, Bio Optica, Milano, Italy); cells were soaked in 
a lithium carbonate solution (for 10 min) to prevent false results caused by the presence of uric acid 
and urates in the samples; then, cells were treated with a silver nitrate solution, left in dark for  
1 h, and then a reduction solution was applied for 5 min; then, samples were treated with a sodium 
sulphite solution for 5 min and with a Mayer’s Carmalum solution to contrast the calcium deposits. 
The intracellular calcification was evaluated by optical microscope (XDS-2 + M-795 model,  
Optika Microscope, Milano, Italy) and images of H9c2 cell line in von Kossa staining were captured 
using a digital camera (DIGI-full HD video/photo camera, Optika Microscopes, Milano, Italy) and 
then analyzed. 
2.7. Statistics 
All values are means ± standard error (SE) for at least three determinations. Differences between 
experimental points were evaluated by Student’s t-test. p was considered statistically significant when 
p < 0.05. 
3. Results  
3.1. Cell Viability and Proliferation 
Data obtained from cell viability assay show that treatment for 48 h with vitamin D3 or paricalcitol 
induces a similar dose-dependent response. In particular, [1 nM], [10 nM], and [100 nM] vitamin D3 
and paricalcitol induce a statistically significant increase in cell viability in comparison to untreated 
control cells, as well as in comparison to cells treated with appropriate vehicles alone (Figure 1).  
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Figure 1. Cell viability assay in H9c2 cells shows that [1 nM], [10 nM], and [100 nM] 
Vitamin D3 and Paricalcitol induce no significant differences in cell viability in comparison 
to control cells (both untreated and treated with appropriate vehicles). On the contrary, a 
significant difference (p < 0.05) is observed when H9c2 are treated with [300 nM]  
vitamin D3. Data are expressed as means ± S.E.M. (standard error of the mean) vs. control. 
* Statistically significant difference (p < 0.05) of vitamin D3 (or paricalcitol) vs. controls 
(untreated cells and vehicles). Black dot indicates a statistically significant difference 
between vitamin D3 and paricalcitol. 
 
However, when cells are treated with [300 nM] vitamin D3 or [300 nM] paricalcitol a significant 
difference (p < 0.05) in cell viability occurs (Figure 1); vitamin D3 induces an increase in cell viability 
while paricalcitol induces a significant decrease. 
Since cell viability is correlated, but not completely superimposable to cell proliferation, we tested 
the effects of vitamin D3 and paricalcitol on cell proliferation by direct cell count. Results show that 
only when cells are treated with [300 nM] vitamin D3 a significant increase in cell number and density 
occurs (Figure 2). No significant increases in cell number and density are observed comparing controls 
(untreated or treated with appropriate vehicles) to exposed cells with all the other experimental 
concentrations and stimuli (Figure 2). 
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Figure 2. A significant increase in cell density is observed when cells are treated with  
[300 nM] Vitamin D3 in comparison to controls. Data are expressed as means ± S.E.M. vs. 
control. * Statistically significant difference (p < 0.05) of vitamin D3 vs. controls (untreated 
cells and vehicles). 
 
3.2. cAMP Levels 
Data obtained after treatment of H9c2 cells for 48 h, with vitamin D3 and paricalcitol at different 
concentrations, show different trends for the two molecules: vitamin D3 induces a dose-dependent 
increase in cAMP level (even though not statistically significant), while paricalcitol induces  
a dose-dependent decreases in comparison to controls (Figure 3). For [10 nM], [100 nM], and  
[300 nM] paricalcitol, differences in cAMP level are statistically significant in comparison to controls. 
At the same concentrations the differences in cAMP levels induced by treatment with vitamin D3 and 
paricalcitol are also statistically significant. 
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Figure 3. A different pattern in cAMP levels can be observed when cells are treated with 
vitamin D3 or Paricalcitol. Data are expressed as means ± S.E.M. vs. control. * Statistically 
significant difference (p < 0.05) of vitamin D3 (or paricalcitol) vs. controls (untreated cells 
and vehicles). Black dots indicate statistically significant differences between vitamin D3 
and paricalcitol. 
 
3.3. Cell Morphology 
Significant changes in cell morphology are observed when cell are treated with [300 nM] 
paricalcitol. No significant changes are observed when cells are treated both with lower concentrations 
of paricalcitol, and with vitamin D3. Direct observation by contrast light microscopy, as well as after 
Haematoxilyn-Eosin staining, reveals relevant modifications in cell shape between treated and control 
cells (Figure 4). Control cells show a spindle-like shape with an oval nucleus, localized in the central 
part of the cell, and several elongations arising from the cell body. Cells tend to establish contact with 
each other so that cytoplasmic elongations appear sometimes very long and thin (Figure 4A). 
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Figure 4. H9c2 cell morphology analysis by contrast phase microscopy and after 
Haematoxylin-Eosin staining. Panels A: untreated and vehicles treated cells observed by 
contrast phase microscopy (upper panel) and after Haematoxylin-Eosin staining (lower 
panel). Cells are spindle-like and with evidently thin and numerous cytoplasmic 
elongations (arrows). Panels B: cells treated with [300 nM] vitamin D3. Cells do not show 
significant morphological changes in comparison to controls both when observed by 
contrast phase microscopy (upper panel) and after staining (lower panel). Panels C: cells 
treated with [300 nM] paricalcitol in some cases appear roundish and with a reduced 
number of cytoplasmic elongations (arrows). Upper panels: total magnification 150×. 
Lower panels: total magnification 100×. Bars: 100 μm. 
 
Treatment of H9c2 cells with [300 nM] vitamin D3 does not induce significant changes in cell 
morphology (Figure 4B), whereas the same concentration of paricalcitol induce significant 
modification (Figure 4C): a great number of cells appear roundish instead of spindle-like and the 
number of cytoplasmic elongations appears greatly reduced. The changes in cell morphology are 
associated with an increase in cell size. In fact, when cells are treated with [300 nM] paricalcitol but 
not with the same concentration of vitamin D3 a significant difference in cell size can be observed 
(Figure 5). After treatment with [300 nM] paricalcitol, cell diameter increases from 15 ± 1.2 μm (mean 
± S.E.M.) to 20 ± 1.0 μm (mean ± S.E.M.). Cell size, expressed as cell area and calculated by 
appropriate software as described in the Section 2 Materials and Methods, appears about 40% wider: 
after the treatment with [300 nM] paricalcitol cell surface increases from 106.96 ± 7.36 μm2 (mean 
area ± SEM) to 211.16 ± 6.12 μm2 (mean area ± S.E.M.). 
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Figure 5. A significant difference in cell size is observed when cells are treated with  
[300 nM] paricalcitol. Data are expressed as means ± S.E.M. vs. control. * Statistically 
significant difference (p < 0.05) of paricalcitol vs. controls (untreated cells and vehicles). 
Black dot indicates a statistically significant difference between vitamin D3 and paricalcitol. 
 
3.4. Acetylcholine and Cell Viability 
Treatment with [10 μM] acetylcholine induces, as expected, a significant decrease in the 
mitochondrial activity of H9c2 whereas stimulation with [300 nM] vitamin D3 (or [300 nM] 
paricalcitol) induces a significant increase in mitochondrial activity in comparison to control, untreated 
cells (Figure 6). 
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Figure 6. [10 μM] acetylcholine, acting on H9c2 by interaction with muscarinic M2 
receptors, induces a significant decrease in mitochondrial activation in comparison to 
untreated cells. When [300 nM] vitamin D3 and [10 μM] acetylcholine are at  
the same time present in the medium, no changes are observed; on the contrary, when  
[300 nM] paricalcitol and [10 μM] acetylcholine are present in the medium, the effect of 
acetylcholine is abolished. Data are expressed as means ± S.E.M. vs. control.  
* Statistically significant difference (p < 0.05) of paricalcitol vs. controls (untreated cells 
and vehicles). ** Statistically significant difference (p < 0.05) of paricalcitol + 
acetylcholine vs. acetylcholine. Black dot indicates a statistically significant difference 
between vitamin D3 and vitamin D3 + acetylcholine. 
 
When [10 μM] acetylcholine and [300 nM] vitamin D3 are simultaneously present in the culture 
medium, no significant changes are observed in comparison to treatment with acetylcholine alone, but 
when [10 μM] acetylcholine and [300 nM] paricalcitol are used (instead of vitamin D3) the effect of 
the neurotransmitter is completely counteracted. 
3.5. Cell Calcification 
Figure 7 shows the effect of Vitamin D3 and Paricalcitol on intracellular calcification occurring in 
H9c2 cardiomyocytes. [300 nM] Vitamin D3 induces a significant increase in calcium incorporation in 
the cells in comparison to control cells (Figure 7A,B). [300 nM] Paricalcitol does not have a 
statistically significant effect on calcium content in H9c2 cardiomyocytes in comparison to control, 
untreated cells (Figure 7C). 
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Figure 7. Effect of vitamin D3 and paricalcitol on intracellular H9c2 calcification.  
Panels A: control and vehicles treated cells. A background weak intracellular  
calcification is present: colored dots (dark pink) are evident into the cell cytoplasm.  
Panels B: [300 nM] vitamin D3 treatment induces a strong intracellular calcification in 
H9c2. Panels C: [300 nM] paricalcitol induces an intracellular calcification at the same 
extent of that observed in controls. Upper panels: total magnification 100×. Lower panels: 
total magnification 200×. Bars: 100 μm. Panel D: percentage of calcification area.  
* Statistically significant difference (p < 0.01) in calcification induced by vitamin D3 vs. 
controls (untreated cells). Black dot indicates a statistically significant difference  
(p < 0.01) in calcification induced by vitamin D3 vs. paricalcitol. 
 
 
4. Discussion 
Recent observational studies provided support for a possible protective role for vitamin D3 in the 
CKD population [1,2]. Recent scientific evidence suggests that vitamin D3 may negatively regulate the 
renin-angiotensin system, inhibit cardiomyocyte hypertrophy and proliferation, as well as modulate 
and suppress the inflammatory response to blood vessel injury [18]. Cardiovascular diseases, 
especially atherosclerosis, have been reported to be the main causes of dialysis-related morbidity and 
mortality [2]. In the development of these vasculopathies, not only are traditional risk factors involved, 
but also CKD-related biochemical changes such as hypocalcemia, vitamin D deficiency and 
hyperparathyroidism, which are considered promoting factors. Previous in vitro studies [19] have 
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demonstrated that endothelial cells stimulated with low Ca
2+
, high advanced glycation end products 
(AGEs), and parathyroid hormone (PTH), responded by increasing the expression and production of 
pro-inflammatory and atherosclerotic parameters such as interleukin 6 (IL6), nuclear factor kappa B 
(NFκB), and endothelial nitric oxide synthase (eNOS). These CKD-related biochemical changes are 
significantly counteracted by vitamin D3 treatment, which induces a decrease in the elevated IL-6 
mRNA expression, positively affects the activity of NFκB, and normalizes the parameters associated 
with the eNOS system.  
On the other hand, other studies highlighted that an excess of vitamin D3 increases the risk of 
hypercalcemia and vascular calcification, thus worsening CV risk and reducing survival in patients 
with CKD [4,20]. In fact, vitamin D3 belongs to the category of general VDR activators, having a wide 
range of affinity for the components of the vitamin D3 system, both for the vitamin D3-binding protein 
and for the nuclear VDR. Among the VDR activators, selective activators such as Paricalcitol play a 
major role in controlling mineral metabolism. These selective molecules act more efficiently on 
parathyroid glands rather than on intestine and bone; this leads both to a lower serum calcium and 
phosphorus increases and to an improvement of hyperplasia of the parathyroid gland and secondary 
hyperparathyroidism [15]. For these reasons, selective VDR activators could provide a vitamin D-like 
protective efficacy without the hypercalcemic and hypophosphatemic collateral effects, thus representing 
a potential therapeutic tool against the cardio-renal syndrome. 
From data presented in this study, it emerges that selective activators of the VDR such as 
Paricalcitol are not only associated with less side effects in comparison to vitamin D3 but they also can 
also act directly on cardiomyocytes inducing morphological changes, differentiation, and variations in 
cell ability to respond to acetylcholine. The most notable differences in vitro were observed at high 
doses; this phenomenon could be interpreted considering the peculiar mode interaction between VDR 
and the genes that it regulates. A differential occupancy of the receptor might in fact be responsible for 
the difference in the array of genes that are being regulated by VDR [21]. 
In fact, one of the most potentially dangerous side effects associated with long term therapy with 
vitamin D3, i.e., intracellular calcification, appears to be much less relevant when the selective 
activator of vitamin D3 axis paricalcitol is used instead. From our results it appears that vitamin D3 and 
its analog paricalcitol activate different signal transduction pathways in H9c2 cells: vitamin D3 induces 
cell proliferation associated with an increase of cAMP, whereas paricalcitol induces, at the same 
concentration, cell differentiation, associated with cAMP decreases. In fact, low levels of intracellular 
cAMP are necessary to induce muscle cell differentiation of different myogenic cell lines [16] such as 
H9c2. It is worth remembering that these cells derive from embryonic rat ventricle; thus, they are not 
yet completely differentiated into non-proliferating myocytes/myotubes and they maintain the 
electrophysiological and biochemical properties of both skeletal and cardiac muscle tissue [16]. Data 
in literature demonstrate that H9c2 cell differentiation is associated with an increase of myogenin 
expression, a typical skeletal muscle protein [16], and with an increase of myotrophin, a protein 
associated with normal cardiomyocyte development [22].  
Treatment with high concentration of paricalcitol also induces a significant increase in cell size. 
Cardiomyocyte hypertrophy occurs in response to numerous agonists [23] and growth factor signaling 
pathways that induce hypertrophy are intimately interconnected with intracellular pathways that link 
changes in calcium homeostasis with the reprogramming of cardiac gene expression [24]. The calcium, 
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calmodulin-dependent protein, phosphatase calcineurin, serves as a point of convergence of these 
different intracellular pathways [25] and has been shown to be necessary and sufficient for 
hypertrophy in response to a wide range of signals in vivo and in vitro [26]. Therefore, cardiomyocyte 
hypertrophy in response to paricalcitol has to be interpreted as an adaptive response that parallels and 
accompanies cell differentiation. Future studies will assess whether this adaptive responses will occur 
also in fully differentiated cardiomyocytes. 
Given the recent interest in the role of vitamin D3 deficiency in CV system and heart functionality 
and integrity, we investigated the effects on heart diastolic function of the components of the  
vitamin D3 axis that are known to be associated with VDR, that are vitamin D3, paricalcitol, and 
GcMAF, and preliminary data demonstrated that the components of the vitamin D3 axis differently 
affect the diastolic function. Diastolic function has been evaluated by a rapid and non-invasive method, 
based on ultrasounds and measuring the interval in milliseconds between aortic closure and mitral 
opening; this interval of time is known as iso-volumetric relaxation time (IVRT) [27]. Physiologically, 
it is the time that it takes to pump free calcium out of the myocardium, to produce relaxation of the 
myofibrils and to allow ventricular filling, and takes all the available free energy in the heart to do so. 
IVRT is inversely related to the cellular free energy so the higher the IVRT is, the lower the cellular 
free energy is. From our data emerged that, while vitamin D3 increased IVRT, paricalcitol significantly 
decreased it, thus demonstrating a positive inotropic effects on the levels of cellular free energy. In 
fact, these results can be interpreted as that paricalcitol increased the cellular free energy, a novel 
positive feature of this analog that had not been described before. The effects of GcMAF were 
comparable to those obtained with paricalcitol. These results can be interpreted considering that 
paricalcitol and GcMAF showed similar, although not superimposable, effects at the cellular and 
organism level in other model systems. In fact, both compounds stimulated cAMP formation in human 
mononuclear cells with the highest effect on the “bb” genotype of the VDR. Both paricalcitol and 
GcMAF inhibited the angiogenesis induced by prostaglandin E1 in the chick embryo chorionallantoic 
membrane [28]. This unexpected effect of paricalcitol suggests that its advantage over vitamin D3 
might be far more ranging than simply being non-hypercalcemic. In fact, the decrease of cellular free 
energy in a chronic condition is at the basis of a number of signs and symptoms that are negatively 
associated with the prognosis. Our observation that paricalcitol and GcMAF show an inotropic effect 
at variance with vitamin D3 opens the perspective of administering this molecule in a variety of 
chronic conditions where the use of vitamin D3, although potentially beneficial, has been discouraged 
by the concomitant and potentially harmful side effects of vitamin D3. Since the majority of the results 
presented in this study have been conducted in vitro in a rat myoblast cell line, not yet completely 
differentiated, the results cannot be directly extrapolated to clinical recommendations. Nevertheless, 
such a model system could provide novel indications that can be applied to the clinic. Thus, 
paricalcitol is a molecule that has been safely used for years and this study demonstrates that it shows 
some novel effects that could be exploited in order to maximize therapeutic effects while, at the same 
time, minimizing side effects. The stimulation of cardiomyocyte viability and differentiation without 
inducing intracellular calcification, and the positive inotropic effect in the absence of hypercalcemia, 
might therefore represent novel fields of application of this molecule. 
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5. Conclusions 
Biochemical modifications, promoting factors and pro-inflammatory interleukins play a crucial role 
in the development of cardiovascular diseases in CKD patients as well as in the increase of mortality in 
most of the chronic diseases. Vitamin D3 treatment counteracts most of the CKD related modifications 
in cellular homeostasis and signaling decreasing the elevated IL-6 mRNA expression, positively 
affecting the activity of NFκB and normalizing the eNOS system. However it has been demonstrated 
that vitamin D3 long-term treatment is strongly related to vascular calcification with consequent 
reduction of patients’ survival. For this reason selective activators of VDR (such as paricalcitol) and 
factors involved in the vitamin D3 axis (as GcMAF) might represent new therapeutic tools both for 
treatment of CKD and for treatment of chronic conditions where the use of vitamin D3, although 
potentially beneficial, has been discouraged for the harmful side effects. 
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